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Calcificationa b s t r a c t
Vascular calcification (VC), an unpredictable pathophysiological process and critical event in patients
with cardiovascular diseases (CVDs), is the leading cause of morbi-mortality and disability in chronic kid-
ney disease (CKD) patients worldwide. Currently, no diagnostic method is available for identifying
patients at risk of VC development; the pathology is detected when the process is irreversible.
Extracellular vesicles (EVs) from endothelial cells might promote VC. Therefore, their evaluation and
characterization could be useful for designing new diagnostic tools. The aim of the present study is to
investigate whether microvesicles (MVs) from endothelial cells damaged by uremic toxin and indoxyl
sulfate (IS) could induce calcification in human vascular smooth muscle cells (VMSCs). Besides, we have
also analyzed the molecular mechanisms by which these endothelial MVs can promote VC development.
Endothelial damage has been evaluated according to the percentage of senescence in endothelial cells,
differential microRNAs in endothelial cells, and the amount of MVs released per cell. To identify the role
of MVs in VC, VSMCs were treated with MVs from IS-treated endothelial cells. Calcium, inflammatory
gene expression, and procalcification mediator levels in VSMCs were determined. IS-treated endothelial
cells underwent senescence and exhibited modulated microRNA expression and an increase in the
release of MVs. VSMCs exposed to these MVs modulated the expression of pro-inflammatory genes
and some mediators involved in calcification progression. MVs produced by IS-treated endothelial cells
promoted calcification in VSMCs.
 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
The leading cause of endothelial dysfunction, which dominates
the landscape of chronic kidney disease (CKD) patients, is the accu-
mulation of uremic toxins that damage the endothelium. It is well-
known that endothelial cell dysfunction is implicated in the devel-
opment of cardiovascular complications [1]. Vascular calcification(VC) is a frequent complication associated with the progressive
deterioration of renal functions in CKD patients, and is a predictor
of cardiovascular morbidity and mortality in these patients. No
specific biomarker of VC has been discovered, and diagnosis exclu-
sively involves radiological analyses [2]. Nevertheless, accumulat-
ing evidence supports the fact that the production of altered
extracellular vesicles (EVs) by endothelial cells could at least par-
tially explain how damage suffered by the endothelial cell extends
to the rest of the cells in the vascular vessel [3] and could con-
tribute to calcium accumulation in the vessel walls.
EVs are subcellular structures produced by most cells under
physiological and stress conditions. EVs are subdivided into 3
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microparticles [4]. MVs play an active physiological role in regulat-
ing the intercellular network involved in tissue reparation and
homeostasis. However, under pathological conditions, altered cells
might release a different number of MVs with an altered pheno-
type and/or atypical cargo, thereby promoting changes in other
cells in adjacent tissues [5–7]. Consequently, MVs produced by
endothelial cells have attracted particular interest, as they can be
quantified in peripheral blood and be used as a biomarker for
endothelial damage [8–10]. Their characterization might provide
information about the mechanism by which endothelial cells could
cause vascular injury and cardiovascular disease (CVD) [11,12].
MVs released by different cells initiate the cascade of events
that culminate with the osteogenic transformation of vascular cells
[13]. Endothelial cells, in particular, produce MVs that act as a sig-
nal for the calcification process in vascular cells [10]. Moreover,
vascular smooth muscle cells (VSMCs) become susceptible to
MVs and undergo a progressive change in their phenotype [14].
In addition, VSMCs reportedly exhibit an inflammatory response
that could mediate the calcification process [15,16].
Though a healthy endothelium modulates homeostasis in the
vasculature, under pathological conditions, it induces an inflam-
matory response-, which results in endothelial damage that might
be subsequently related to endothelial senescence [17,18]. Some
studies have demonstrated that endothelial injury caused by
inflammatory cytokines [17] and uremic toxins [19,20] induces
the development of cellular senescence; therefore, it could modu-
late the production of altered endothelial MVs [21]. Moreover, cells
from the vascular wall rely on MVs to carry out interactions with
the extracellular environment, and such cells that interact with
altered MVs from endothelial damaged cells might promote VC
[10]. However, no studies have investigated the effect of MVs
derived from endothelial cells exposed to uremic toxins, as
observed in CKD patients.
VC is an irreversible and common phenomenon associated with
elderly [10] and CKD [22] patients that actively contributes to the
development of inflammatory CVD [23]. The early identification of
VC in CKD patients or even in the previous steps of this calcification
process, together with the understanding of the physiopathological
mechanism of VC, could be essential for preventing CVD progres-
sion. Unfortunately, VC is a silent disorder [2,20] resulting because
of the activity of a complex network of signals that regulate the
process of bone mineralization, mainly in VSMCs, due to these cells
becoming susceptible to these signals [24]. To date, knowledge
regarding the cellular and molecular mechanisms involved in VC
development is scarce.
This study aims to determine if a uremic toxin such as indoxyl
sulfate (IS) could mediate endothelial damage with the subsequent
production of MVs capable of promoting calcification in VSMCs. In
addition, we have characterized the potential key elements associ-
ated with endothelial MVs and the procalcificant signals induced
by these MVs on VSMCs. This approach could be useful as a diag-
nostic tool in future studies, for identifying patients at risk of VC
and for developing new therapies.2. Material methods:
2.1. Cell cultures
Human umbilical vein endothelial cells (HUVECs, CC-2517, lot
number 323,352 Lonza) were cultured in EGM medium (Lonza)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Sigma). Cultures were maintained at 37 C under 5% CO2 con-
ditions at 95% humidity in the EGMmedium, which was comprised
of endothelial basal media (EBM; Lonza CC-3121), supplementedwith a growth bullet kit (Lonza, CC-4133) containing bovine brain
extract, ascorbic acid, hydrocortisone, epidermal growth factor,
gentamicin/amphotericin-B, and 10% heat-inactivated FBS. Experi-
ments involving HUVECs were performed in cells passaged < 9
times (PD < 20). The rate of population doubling (PD), which
occurred between passages was calculated using the formula
PD = [ln {number of cells harvested} – ln {number of cells
seeded})/ln2].
Human aortic smooth muscle cells (HASMCs, CC-2571) were
obtained from Lonza. Cells were maintained in the SmGM-2 med-
ium (Lonza; CC-3181) supplemented with 20% FBS (Sigma) at 37 C
in a humidified atmosphere containing 5% CO2. HASMCs from pas-
sage 5–7 were used in the experiments.
2.2. Experimental design in IS-treated HUVECs
HUVECs were seeded the day before (day 0) treatment was to
be carried out in EGM medium (Lonza) supplemented with 10%
heat-inactivated FBS (Sigma). The following day (day 1), endothe-
lial cells were treated with IS (indoxyl sulfate; Sigma) dissolved
in DMSO (Sigma) 250 mM for 3 days. On day 4, the media for the
HUVECs were changed, and on the following day (day 5), media
were collected (Fig. 1). Supernatants from each experiment were
pooled, and MVs were isolated as described below. In addition,
control and IS-treated HUVECs were stained, for testing the b-
galactosidase (SA-b-gal) activity, as described further.
2.3. Isolation, quantification, and characterization of microvesicles
MVs from IS-treated endothelial cells were isolated. Briefly, cell
culture supernatants were serially centrifuged (15 min at
3,000 rpm to remove cells and cellular debris, 30 min at
14,000 rpm to concentrate the MVs in Eppendorf centrifuges), as
described by the International Society on Thrombosis and Hae-
mostasis [25]. Pooled MVs from control and IS-treated HUVEC cul-
tures were characterized following International Society for
Extracellular Vesicles (ISEV) guidelines [26], using confocal micro-
scopic analysis for size control, and flow cytometry for quantifying
and analyzing membrane markers by mass spectrometry analysis
[27]. Confocal microscopy analysis results showed that MVs ranged
in size from 0.3 to 1.2 lm. Pooled MVs from control and IS-treated
endothelial cells were mixed in equal amounts and after that they
were characterized and quantified in terms of size, using the Beck-
man Coulter Cytomic FC 500 flow cytometer, with CXP software.
The occurrence of MVs was understood to be gated events and
their size was assessed from a side scatter (SSC) vs. forward scatter
(FSC) dot-plot, which was produced in a standardization experi-
ment using the SPHEROTM Flow Cytometry Nano Fluorescent Size
Standard Kit (Spherotech). The latter has size-calibrated fluores-
cent beads ranging in size from 0.22 to 1.35 lm in diameter. Events
in which the size was less than 0.22 lmwere adequately excluded
while distinguishing real events from those in the background;
events in which the size was >1.35 lm were excluded, to prevent
them from possibly being confused with apoptotic bodies [28].
Mass spectrometry analysis was performed as previously
described [27], and showed the presence of different proteins that
in the ISEV guidelines are suggested as markers for the four cate-
gories of proteins that are recommended should be checked: tetra-
spanin and lactadherin (category 1), annexins and syntenin
(category 2), cytochrome c and HSP90B1 (category 3), and fibro-
nectin, collagen a and MMP14 (category 4).
Moreover, MVs from the HUVEC culture medium were charac-
terized with regard to their protein profiles, as shown below.
Double-fluorescent labeling was performed to confirm the protein
profile of the MVs obtained from HUVECs. Characterization was
performed by incubating endothelial MVs with fluorescein
Fig. 1. Schematic diagram of the experimental design to obtain for endothelial cells (HUVECs) model.
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Pharmingen) and phycoerythrin-annexin A5 (BD Pharmingen), in
annexin A5-biding buffer (10 mM HEPES, 7.4 pH, 140 mM NaCl,
2.5 mM CaCl2). An equal volume of Flow-Count calibration beads
(Beckman Coulter) was added to measure the number of events
per microliter. Isotype negative controls were also prepared. A
sample with fluorescein-conjugated annexin A5 and a CaCl2-free
solution was used as a control for annexin A5 labeling. To confirm
the exclusion of apoptotic bodies during MVs isolation, the DNA
content of the HUVEC-derived MVs was determined, by incubating
them with acridine orange (Invitrogen), till a final concentration of
20 mM was achieved.
2.4. Analysis of senescence-associated b-galactosidase (SA-b-gal)
activity
SA-b-gal staining was performed using the senescence-
galactosidase staining kit (Abcam, Catalog #ab65351), according
to the manufacturer’s protocol. In brief, on day 5, control and IS-
treated endothelial cells were washed with PBS and fixed in fixing
solution for 12 min at room temperature. Next, they were washed
in PBS to remove the fixing solution and incubated in freshly pre-
pared SA-b-gal at 37 C for 16 h without CO2. At the end of the
incubation period, SA-b-gal-positive cells (senescent cells) were
identified as blue-stained cells under a standard light microscope.
The number of blue colored positive cells was counted and normal-
ized to the number of total cells in the same field. The percentage
of SA-b-gal-positive cells was calculated in 8 randomly selected
microscopic fields (magnification 100X).
2.5. Electron microscopy
For the microanalysis of ions, SEM-EDX (Scanning Electron
Microscopy-Energy Dispersive Microanalysis System) analysis
was performed, using the JEOL-SEM JSM-7800 LV scanning micro-
scope. Prior to analysis, MVs samples were diluted in PBS, placed
under coverslips, allowed to dry at room temperature, and further
fixed in 2% glutaraldehyde for 24 h, at 4 C. Subsequently, the MVs
were dehydrated in ethanol and dried using the routine critical
point drying procedure for SEM analysis. The prepared MVs were
platinum coated (1.5 nm) in a Polaron E5400 metal evaporator
(BioRad).
2.6. Treatment of HAMCs with MVs and determination of
mineralization levels
HASMC mineralization levels were analyzed via qualitative
staining, using alizarin red. HASMCs (10000 cells/well, 24-well
plates) were cultured with 50,000 MVs/mL from the control and
IS-treated HUVECs groups for 9, 20, and 30 days in 2% FBS-
supplemented DMEM. Cells exposed to 2% FBS-supplemented
DMEM containing 2.0 mM inorganic phosphorus (Pi; pro-
calcifying condition) were used as a positive control. Culture med-ium was renewed every 2 days. The detection and quantification of
mineral deposits was performed via alizarin red staining. Briefly,
samples were fixed (50% ethanol 5 min, 95% ethanol 5 min),
stained for 5 min with alizarin red S (40 mM, pH 4.2; Sigma), rinsed
with 50% ethanol, and subsequently scanned. At the end of the
incubation period, images of cells stained with alizarin red S were
captured using a phase-contrast inverted light microscope (Optika;
magnification 100X).
2.7. Assessment of calcium deposits
After an incubation period of 30 days, mineralization levels
were determined. Cells were decalcified with 0.6 N HCl overnight
at 4 C. The calcium content of supernatants was determined by
spectrophotometry, using a kit containing phenolsulphoneph-
thalein dye (no. DICA-500, QuantiChrom calcium assay kit; BioAs-
say Systems). Then, cells were washed three times with PBS
(Sigma) and solubilized in 0.1 M NaOH/1% SDS. The protein content
was measured using the BCA protein assay kit (Pierce), and the cal-
cium content was normalized to the total protein content. The cal-
cium content in the cells was expressed in terms of lg/mg protein.
2.8. Real-time PCR
Total RNA was extracted from control and IS-treated HUVECs, as
well as MVs-treated HASMCs using the mirVana PARIS RNA and
Native Protein Purification Kit (Ambion), according to the manu-
facturer’s instructions. cDNA was synthesized using the High
Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
California, USA), using 2 mg of total RNA primed with random hex-
amer primers, as per the manufacturer’s instructions. Real-time
polymerase chain reactions (PCR) were performed using
the ABI Prism 7500 sequence detection PCR system (TaqMan
Universal Master Mix II, No AmpErase UNG; Applied Biosystems),
as per the manufacturer’s protocol. The assay IDs used
were as follows: Runx2, Hs001047973_m1, BMP2, Hs00154192_
m1, TWEAK (Hs00387540_g1), CCL2 (Hs002344140_m1),
CCL5 (Hs00982282_m1), TNF-a (Hs00174128_m1) and, IL-6
(Hs00174131_m1) and, HPRT1, Hs02800695_m1 (as normalized
assay). The mRNA copy numbers were calculated for each sample
with instrument software, using a comparative threshold (Ct)
value. The relative fold-change was determined using 2  DDCt
methods, using control MVs-treated HASMCs as the baseline; their
levels were normalized to HPRT1 expression levels.
2.9. Real-time PCR of mature microRNAs
Total RNA was extracted from control and IS-treated HUVECs.
Total RNA was isolated using the mirVana PARIS RNA and Native
Protein Purification Kit (Ambion), according to the manufacturer’s
instructions. The miRNA targets were reverse transcribed using a
pool of RT primers obtained from TaqMan Small RNA Assays
(Applied Biosystems) and total RNA, using the TaqMan MicroRNA
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were kept on ice for at least 5 min, followed by incubation in a
thermal cycler at 16 C for 30 min, 42 C for 30 min, 85 C for
5 min, and were kept at 4 C. A micro-NTC (no-template control)
that contained no sample RNA was included in these reverse-
transcription reactions. Subsequently, quantitative real-time PCR
was performed in a PCR reaction mixture using the 20  TaqMan
miR Assay, which included PCR primers and probes (50-FAM), and
2  TaqMan Universal Master mix with no UNG (Applied Biosys-
tems) and RT products. The reaction mixture was first incubated
at 95 C for 10 min, followed by 40 cycles at 95 C for 15 s and
60 C for 1 min. The following assay IDs were used: hsa-miR-
126-3p (assay ID 002228), hsa-miR-126-5p (assay ID 000451),
hsa-miR-155 (assay ID002623), hsa-miR-21-3p (assay ID
000397), hsa-miR-21-5p (assay ID 002438), hsa-miR-210 (assay
ID 000512), hsa-miR-125b (assay ID 000449), hsa-miR-150 (assay
ID 000473), hsa-miR-1915 (assay ID 121111_mat), hsa-miR-601
(assay ID 001558), hsa-miR-575 (assay ID 001617), and U6 snRNA
(assay ID 001973); all these materials were purchased from
Applied Biosystems. The relative amounts of each miRNA were cal-
culated using the comparative threshold (Ct) method, by determin-
ing the DCt, Ct(miRNA)  Ct(U6 snRNA) values in endothelial cells.
The miRNA copy numbers were calculated for each sample with
instrument software, using Ct values. The relative miRNA expres-
sion level was calculated using the 2 DDCt method, using control
HUVECs as the baseline, whose levels were normalized to U6
snRNA (internal control miRNAs) expression levels.
2.10. Western blot analyses
Extracts from control, IS-treated endothelial cells, as well as
controls and MVs-treated HASMCs were lysed using the CytoBuster
Protein Extraction Reagent lysis buffer (Millipore), containing a
protease and phosphatase inhibitor cocktail (Roche). The total pro-
tein content of the lysates was quantified using a BCA Protein
Assay Kit (Pierce), using BSA as a standard. Briefly, equal amounts
of proteins (20–50 lg protein/lane) were diluted with the reducing
sample buffer and separated via SDS/PAGE (10% gel), under reduc-
ing conditions. Samples were then transferred onto nitrocellulose
membranes (BioRad), blocked in TBS containing 0.1% Tween 20
and 5% dry non-fat milk for 1 h at room temperature. They were
probed using the following primary antibodies in the same buffer,
at different dilutions: Cyclin D1 (Thermo Scientific, Cat. No. RM-
9104-SO, dilution 1/1000, 36 kDa), Lamin B1 (Abcam, ab133741,
dilution 1/1000, 66 kDa), SM22a (Santa Cruz Biotechnology, sc-
53932, dilution 1/500, 22 kDa), and GAPDH (Millipore, Cat No.
MAB374, dilution 1/2000, 38 kDa); a-tubulin from Sigma (T5158;
loading control) was used as a loading control. After washing, the
membranes were incubated with Novex horseradish peroxidase-
conjugated secondary antibodies (1:5000). Bands were visualized
with the Luminata Crescendo Western HRP substrate (Millipore).
The quality of proteins and efficacy of protein transfer was evalu-
ated by Red Ponceau (Sigma) staining. Bands were quantified using
Image J software (NIH) and protein levels were normalized to anti-
GAPDH or anti- a-tubulin levels in HUVECs or HASMCs,
respectively.
2.11. Statistical analysis
Data were expressed as means ± SD values. The Student’s t-test
(2-tailed p-values) or Mann-Whitney test was used for comparing
variables that were either normally or not normally distributed,
respectively, in two groups. Otherwise, statistical significance
was determined using ANOVA, followed by the Kruskal-Wallis test.
Values less than 0.05 were deemed to correspond to differences
between means of two independent experiments that are statisti-cally significant. A p-value of <0.05 was considered to be statisti-
cally significant, wherein *p < 0.05, **p < 0.01, and ***p < 0.001.
GraphPad Prism 6 was used to determine the statistical
significance.3. Results
3.1. IS treatment-induced senescence in HUVECs
HUVECs treated with IS were characterized by a significant
increase in senescence-associated b-galactosidase (SA-b-gal)
stained cells, as compared to that in control cells. IS-treated senes-
cent cells underwent a change in the cell morphology and adopted
a typical flattened and enlarged morphology (Fig. 2A). The percent-
age of senescent cells was determined by testing the SA-b-gal
activity. The number of SA-b-gal-positive (senescent) cells was sig-
nificantly increased in IS-treated HUVECs. Strikingly, although all
IS exposure experiments were performed under the same condi-
tions, the percentage of positive cells was diverse. As a conse-
quence of this variation and based on previous studies (Alique
et al., 2019), two distinct and significant groups with different
senescence percentages emerged: one group had an intermediate
or medium percentage of senescent cells (42.85 ± 4.72%), while
the other had an elevated or high percentage of senescent cells
(72.90 ± 13.09%), as compared to the percentage of non-treated
endothelial cells (7.07 ± 2.87%) (Fig. 2B). The senescent phenotype
was more characteristically present in the group exhibiting higher
senescence levels than in the group exhibiting intermediate levels
of senescence. The criterium applied to divide into 2 groups was
based on a previous study (Alique et al., 2019) in an endothelial
replicative senescence, a senescence-associated secretory pheno-
type (SASP) where endothelial cells achieved up to 69% (69.36 ± 1
1.30%) of senescence, similar to the IS-treated group called with a
elevated or high percentage of senescent cells (72.90 ± 13.09%), a
stress-induced premature senescence (SIPS). The second IS-
treated group is defined as intermediate or medium percentage
of senescent cells associated with a percentage of 42.85 ± 4.72%
and presents a lower percentage of senescence compared with
endothelial replicative senescence as previously reported (Alique
et al., 2019).
To confirm the senescent phenotype, protein senescence mark-
ers were tested. Cyclin D1 and Lamin B1 protein levels were mea-
sured via Western blot analysis. When the senescence levels were
intermediate or elevated, IS-treated endothelial cells showed
Lamin B1 downregulation, as compared to control endothelial cells
(Fig. 2C and 2D). Whereas, Cyclin D1 levels were only significantly
decreased during the IS-induced elevation in senescence levels.
Thus, these data confirm that cells treated with IS for 3 days gen-
erated senescent endothelial cells, which validates our model
in vitro.3.2. MicroRNA expression in IS-treated HUVECs
Next, we studied about how microRNAs were implicated in
endothelial damage, resulting in the senescent phenotype, as a
consequence of changes introduced in endothelial cells via the
stimulus provided by IS treatment. Therefore, the expression levels
of miR-126 (3p and 5p), miR-21 (3p and 5p), miR-155, miR-210,
miR-125b, miR-150, miR-1915, miR-601, and miR-575 in HUVECs
have been analyzed in this study (Fig. 3). The results showed that
the number of both types of miR-126 strands decreased among
the endothelial cells exhibiting IS-induced elevated percentages
of senescence. In the case of miR-21, only miR-21-3p was down-
regulated in IS-induced elevated senescence in cells, while the
strand miR-21-5p was not modified. MiR-155 levels were also
Fig. 2. Senescence in HUVECs. HUVECs develop a senescence phenotype after IS treatment (250 mM; 3 days). The percentage of senescent HUVECs was determined by
senescence-associated b-galactosidase staining. (A) Phase-contrast microscopy pictures. (B) The data represent means ± SD and are expressed as a percentage of total cells
and fold induction, with regard to control values. Control (n = 6); IS-induced intermediate senescence (n = 4); IS-induced elevated senescence (n = 4); 8 random fields each;
magnification, x100. (C) Lamin B1 and Cyclin D1 representative Western blots under different conditions. After probing with GAPDH, it was confirmed that equal amounts of
proteins were loaded. (D) The graphs show that densitometric band analysis levels were normalized to GAPDH levels in arbitrary units (AU). In B and D, data represent
means ± SD values and are expressed as the fold induction, as compared to control values. Control (n = 6); IS-induced intermediate senescence (n = 4); IS-induced elevated
senescence (n = 4). *p < 0.05, **p < 0.01, and ***p < 0.001. Control HUVECs vs. IS-treated HUVECs.
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Fig. 3. miRNAs in IS-treated HUVECs. qPCR analysis of miR-126-3p (A), miR-126-5p (B), miR-21-3p (C), miR-21-5p (D), miR-155 (E), and miR-210 (F) was performed in
control and IS-treated endothelial cells using the DCt method; U6 snRNA was used for normalization in HUVECs. *p < 0.05 and ***p < 0.001 for Control vs. IS-induced
intermediate senescence. Control (n = 6); IS-induced intermediate senescence (n = 4); IS-induced elevated senescence (n = 4).
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and only miR-210 levels were increased in both groups of senes-
cent HUVECs. These miRNAs were involved in endothelial home-
ostasis and regulated by IS treatment.
Moreover, we have also measured the levels of some miRNAs
associated with endothelial cell damage caused by IS treatment
[20]. However, there were no changes in the levels of miR-125b,
miR-150, miR-1915, miR-601, and miR-575 in IS-induced senes-
cence groups, with regard to the control (Fig. 1S); consequently,
they did not appear to be involved in the damage caused by IS in
endothelial cells.
3.3. MVs released and annexin A5 expression
We have also determined the number of MVs in IS-treated and
control HUVECs. The number of HUVEC-derived MVs was assessed
by flow cytometry (number/mL), and the number of endothelial
cells was measured using the Neubauer chamber. Annexin A5, a
phosphatidylserine (PS) binding protein, is commonly used to
characterize MVs, and during MVs formation, the presence of PS
is confined to the exoplasmic membrane leaflet and exposed in
the MV surface. A representative analysis is shown in Fig. 4 (A-D)
The ratio was expressed as the fraction between the MVs num-
ber/HUVECs number (MVs per cell ratio). Remarkably, a significant
(p < 0.001) increase in the production of MVs per cell was observed
during IS-induced elevated senescence (9.92 ± 4.29, n = 4), as com-
pared to the control (1.68 ± 1.00, n = 6); an insignificant increase (2.
88 ± 1.17, n = 4) was also observed in the IS-induced intermediate
senescence group (Fig. 4E).
Thus, besides the MVs per cell ratio, we have studied PS expo-
sure in the MVs. No changes were detected in annexin A5 expres-
sion by flow cytometry (expressed by mean fluorescence intensity;
MFI) in the control and IS-treated HUVEC MVs (Fig. 2S).
3.4. MVs from IS-induced elevated senescent endothelial cells contain
calcium
Following the characterization of MVs, scanning electron
microscopy-energy dispersive X-ray spectroscopy (SEM-EDX) was
performed to detect whether MVs contained calcium or other ions.
EDX elemental analysis revealed that the mean calcium content in
MVs from IS-treated endothelial cells, determined from several
regions in each sample, was 12-fold more than that of MVs from
untreated endothelial cells (Table 1). Besides, IS-treated HUVECs-
derived MVs contain higher levels of magnesium than control
HUVECs, and no changes were detected for other ions, such as
phosphorus and potassium. Moreover, the calcium content in
MVs was measured with a SEM-mapping micrograph, which
showed that calcium was homogeneously distributed into MVs
from control and IS-treated endothelial cells.
3.5. MVs released from IS-treated HUVECs induced calcification in
HASMCs
To evaluate the possibility that MVs from IS-treated HUVECs
resulted in calcification, human aortic smooth muscle cells
(HASMCs) were cultured in the presence of MVs (50,000 MVs/
mL) from control and IS-treated HUVECs for 9, 20, and 30 days.
In HASMCs, calcium deposits were evaluated using alizarin red
on different days (Fig. 5 and Fig. 3S). MVs from both groups of
IS-treated endothelial cells induced calcification after 30 days of
treatment, notably in MVs from IS-induced elevated senescence.
Calcium deposits were not observed in HASMCs with MVs from
control endothelial cells. HASMCs were also incubated with phos-
phate, to induce a calcification condition, as a positive control; in
the negative control, HASMCs were grown without MVs. To con-firm these findings, the calcium content was quantified using a col-
orimetric method based on phenolsulfonephthalein reagent,
30 days after the presence of MVs was observed (Fig. 5B). Calcium
accumulation caused by MVs from IS-treated HUVECs was signifi-
cantly increased in HASMCs on day 30, as compared to HASMCs
without MVs. Significant differences were also observed in the
development of calcification on day 30, between both groups of
MVs obtained from IS-treated HUVECs (Fig. 5B).
3.6. MVs from IS-treated HUVECs increased pro-calcification genes in
HASMCs
The expression of pro-calcifying genes in HASMCs was analyzed
by qPCR. The results demonstrated that MVs from both groups of
IS-treated endothelial cells induced Runx2 and BMP2 expression,
via two essential procalcifying genes (Fig. 6A). Concretely, MVs
from IS-induced intermediate senescent cells increased Runx2
gene levels in HASMCs over the longest treatment duration
(30 days), whereas BMP2 gene expression was augmented 20
and 30 days after MV treatment. However, for MVs obtained from
IS-induced elevated levels of senescent cells, Runx2 gene levels
were elevated after 9, 20, and 30 days, and BMP2 levels were
increased after 20 and 30 days of treatment.
To corroborate the procalcifying vascular phenotype, the
expression of a specific HAMSCs marker (SM22a) was evaluated.
Western blot assays established that SM22a levels were dimin-
ished in HASMCs after treatment with MVs from IS-treated
HUVECs on day 20 and 30 (Fig. 6B).
3.7. MVs released from IS-treated HUVECs modulated inflammatory
genes in HASMCs
To elucidate the effect of the inflammation on the progression of
calcification, we performed qPCR analysis for genes expressing dif-
ferent pro-inflammatory cytokines (TNF-a, TWEAK, CCL2, CCL5,
and IL-6) that were implicated in the calcification process in
HASMCs.
Our results showed that TWEAK (cytokine tumour necrosis
factor-like weak inducer of apoptosis) mRNA levels were decreased
in HASMCs treated with MVs from IS-treated endothelial cells on
day 20 and 30 (Fig. 7A). However, TNF-a caused a significant
increase in the number of HASMCs treated with MVs obtained from
the IS-induced intermediate senescence group and a significant
decrease in the IS-induced group exhibiting elevated senescence
(Fig. 7). Furthermore, other inflammatory mediators, such as
CCL2 and CCL5 were also evaluated. The chemokine mRNA levels
of both these mediators increased significantly in HASMCs after
treatment with MVs from the cells exhibiting IS-induced interme-
diate senescence; however, no changes were observed in the ele-
vated senescence group (Fig. 7B and C). Finally, we evaluated the
expression of IL-6, a cytokine linked with chronic inflammation.
The results showed that IL-6 gene expression levels were signifi-
cantly reduced in MVs-treated cells on day 20, whereas it was sig-
nificantly overexpressed in cells treated with both groups of MVs
on day 30 (Fig. 7E).4. Discussion
VC is characteristically observed in CKD, and is associated with
the damage induced by uremic toxins and other substances in vas-
cular cells [2]. The identification of VC in CKD patients seems to be
critical to prevent the progression of CVD, which is a principal
cause of morbi-mortality in these patients. Moreover, some studies
resported that some uremic toxins, such us IS and p-cresyl sulfate,
trigger calcification in vessels throught endothelial dysfunction of
Fig. 4. Characterization and measurement (MVs per cell ratio) of MVs generated by IS treatment in HUVECs. Representative graphs showing the results of flow cytometry
analysis of MVs (A-D). Fluorescence-gated beads with sizes between 0.22 mm and 1.35 mm were used for determining gates(A,B). MVs were plotted using an FSC logarithmic
(FS log)/SSC logarithmic (SS log) dot-plot histogram and were gated in the window selected above; it was necessary to use bead counts in each experiment, to calculate the
concentration of MVs per unit volume of the sample (C). Size-selected MVs are plotted as a function of their double fluorescence for specific Annexin A5-PE binding and CD31-
FITC (D). (E) The number of HUVEC-derived MVs was assessed by flow cytometry, and the number of endothelial cells was measured using the Neubauer chamber. The ratio
was expressed as the fraction of MVs number/HUVECs number in each experiment (MVs per cell ratio). Control (n = 6); IS-induced intermediate senescence (n = 4); IS-
induced elevated senescence (n = 4). **p < 0.01, control HUVECs vs. IS-induced elevated senescence. #p < 0.001, IS-induced intermediate senescence vs. IS-induced elevated
senescence.
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evaluate the initial steps during VC formation and CKD patients
at risk of developing VC, and this pathology is detected when the
process is irreversible [2].Recently, different studies have supported the role of MVs pro-
duced by many cells that promote VC [32–34], which shows that
MVs have novel roles in VC, although their potential use as VC
biomarkers is still unknown. Some reports have demonstrated that
Table 1
EDX analysis of control and MVs from IS-treated elevated senescent cells. The relative
percentage of ion content in MVs obtained from control and IS-treated HUVECs.
Control (n = 4); elevated senescence group (n = 4). *p < 0.05 and ***p < 0.001, ns: not






senescence (Mean ± SD)
p-value
Calcium 0.495 ± 0.439 6.020 ± 1.762 ***(0.001)
Magnesium 0.178 ± 0.022 0.583 ± 0.324 *(0.047)
Phosphorus 1.050 ± 0.501 1.440 ± 0.616 ns
Potassium 6.460 ± 1.914 6.217 ± 1.452 ns
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biomarkers in patients with CVD [3,35,36]. However, the clinical
application of the MVs for the prognosis of disease could have
some limitations, due to the origin of cells that produce MVs. It
has been reported that the measurement of specific MVs from each
kind of cell is essential for characterizing specific surface markers
[37]. The results of this study extend the use of endothelial MVs
to identified CKD patients at risk of developing VC. Besides, the fact
that endothelial MVs released from endothelial cells undergo IS-
induced senescence and promote calcification in VSMCs might
offer new perspectives that would enable the development of ther-
apies based on the modification of the procalcifying actions of
these MVs.
Uremic toxins promote endothelial dysfunction in CKD patients.
Accumulating pieces of evidence support the fact that among other
cells, endothelial cells undergo premature senescence induced by
uremic toxins [38–40]. IS treatment restrains the number of cell
divisions that occur and cause endothelial cells to achieve SIPS,
which is characterized by an irreversible arrest in the cell cycle
[41]. SIPS is a physiopathological CVD mechanism associated with
CKD [42]. In our in vitro model, an increasing percentage of senes-
cent cells have been observed in the endothelial cells throughout
the process of culturing of cells with IS. This uremic toxin gener-
ates premature endothelial senescence in different proportions,
thus highlighting the susceptibility of the endothelial cells in pri-
mary culture, because of their limited lifespan. Perhaps, the results
highlighted the sensitivity of primary culture cells of IS-treated
HUVECs. Because primary cells are derived from tissue and not
modified, they are more similar to the in vivo state and exhibit a
normal physiology.
Moreover, primary endothelial cells have a limited lifespan, and
IS treatment abrogates cellular division; cells become senescent in
an experiment-dependent fashion. Notably, the expression of
Cyclin D1, a protein that played a critical role in the cell cycle
and whose levels are reportedly elevated during senescence pro-
cess [43], was diminished in IS-induced elevated senescent cells.
This data indicated that this type of senescence might have
occurred in the endothelium; in this case, SIPS could be induced
by IS, and regulate the proteins involved in the cell cycle and,
therefore, in senescence (SASP and SIPS).
Recent studies have shown that miRNAs are critical modulators
of endothelial homeostasis due to their role in controlling endothe-
lial cell functions and, therefore, are implicated in vascular dys-
function [44]. miRNAs have been associated with some chronic
and irreversible pathologies, such as atherosclerosis [44,45] and
in CKD-associated CVD [46]. We have observed that IS treatment
modifies the expression of some miRNAs in HUVECs; in particular,
miR-126, miR-21-3p, and miR-210 levels are altered in cells trea-
ted with IS; more precisely, the levels of both strands of miR-126
were decreased in IS-treated endothelial cells, and the modulation
was associated with the senescence percentage in endothelial cells.
MiR-126 is an essential miRNA involved in homeostasis and senes-
cence in endothelial cells [43,47], and is associated with endothe-
lial shear stress [44]. Furthermore, miR-210 plays a critical role inthe vasculature due to mediated angiogenesis in endothelial cells
[48]. In general, miR-126, miR-21-3p, and miR-210 are associated
with endothelial functions and are modulated by IS, which indi-
cates that this toxin induced changes in the miRNA content of
MVs, and could be involved in the development of pathologies in
the vasculature and therefore contribute to the development of
CKD-associated CVD.
Besides, endothelial cells damaged by the uremic toxin IS pro-
duced a large amount of MVs. Our results showed that the release
of MVs was incremented in IS-treated endothelial cells and was
perhaps associated with the percentage of senescent endothelial
cells. With regard to the delivery of MVs from endothelial cells,
some studies showed that damaged endothelial cells release an
increased number of MVs [5,6], which confirms our data obtained
using IS treatment. This data represents an advantage in identify-
ing CKD patients with an endothelial injury.
Recently, our group has reported about how senescent endothe-
lial cells produce MVs that trigger the development of VC [10].
Another useful hint to confirm this intriguing question is that the
induction of premature senescence by uremic toxins, a pathologi-
cal mechanism in CVD associated with CKD, generate MVs which
could modify VSMCs. Our experimental approach is based on vas-
cular cells exposure to MVs from IS-treated endothelial cells, these
MVs have a high content of calcium (up to 12 times more of cal-
cium than MVs from control endothelial cells) and could increase
the VSMC susceptibility to bone transformation and, therefore,
could promote VC. Our previous results demonstrated that MVs
delivery from a model of replicative endothelial senescence (SASP)
was able to produce calcium accumulation in VSMCs at day 9 [10].
The present results confirmed the fact that MVs from damaged
HUVECs caused a progressive level of calcium accumulation in
VSMCs, which was maximized at day 30. These data confirm that
the effect of endothelial MVs on premature senescence in CKD
patients causes VC, in the same manner as that observed during
physiological aging (replicative senescence model in vitro); how-
ever, both processes presented differences with regard to VC devel-
opment. Remarkably, during replicative endothelial senescence
(SASP), generated MVs caused VC for shorter durations, while dur-
ing IS-induced senescence in endothelial cells, the release of MVs
caused VC for longer durations. Even though VC development is
the final step in both cases, calcium accumulation in MVs of senes-
cent endothelial cells occurs in a different manner, because the
time points at which calcium deposits appear are different and
depend on the type of senescence, i.e. SIPS or SASP. During SASP,
endothelial MVs caused VC for shorter durations, while during
SIPS, MVs released by damaged endothelial cells caused VC for
longer durations. Thereby, endothelial MVs in vascular vessels
might not all be equal in number, and specific MVs present prior
to and during the VC process might have been targeted, to prevent
the pathology from appearing in CKD patients. These results eluci-
date a common mechanism underlying premature aging and age-
associated VC, and differences in the timeline during which MVs
caused VC to develop were identified, depending on the kind of
senescence induced by the stimulus (IS) or physiology. Recently,
Panfoli et al. [49] described MVs as promising biological tools for
diagnosis and therapy. The targeting of specific MVs in the begin-
ning of the developmental period and during the late stages of VC
might be useful for preventing the pathology from appearing in
CKD patients.
Increasing evidence has shown that endothelial inflammation
and senescence significantly contribute to multiple vascular dis-
eases, including atherosclerosis [47]; in fact, the injury of the
endothelium provokes the release of some mediators that act as
pro-inflammatory cytokines [39,40]. The results of our study have
demonstrated that pro-inflammatory cytokines mediate the
development of VC. Previous results showed that senescence is a
Fig. 5. Induction of calcification in HASMCs. HASMCs were cultivated with 50,000 MVs/mL from the control and IS-treated HUVECs for a different number of days. (A)
Qualitative calcification was performed by staining cells with alizarin red. A representative from five different experiments is shown. (B) Calcium content was determined by
spectrophotometry using phenolsulphonphthalein dye after 30 days of treatment. The graphs present the calcium content of the cells, expressed as lg/mg protein. The data
represent the means ± SD of 3 independent experiments. **p < 0.05 vs. control w/o MVs; *** p < 0.001 vs. control w/o MVs, and # p < 0.001 vs. IS-induced intermediate
senescence MVs at the same time.
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fore, by the release of pro-inflammatory factors [50]. We have
tested the expression of cytokines associated with the pro-
calcification process, to demonstrate that TWEAK, a member of
the tumor necrosis factor (TNF) superfamily, recently described
as a biomarker of CVD and directly implied in osteogenic transition[51], and TNF-a -which enhances calcification [52], were modu-
lated in HASMCs with MVs of IS-treated endothelial cells. TWEAK
can regulate cell proliferation, migration, differentiation, death,
inflammation, fibrosis, and angiogenesis [53–56]; it has a synergic
effect in vitro on the promotion of mineralization (osteogenic tran-
sition) induced by inorganic phosphate in HAMSCs [51]. We have
Fig. 6. HASMCs calcification markers. (A) qPCR analysis of Runx2 and BMP2 mRNA obtained from MVs-treated HASMCs using the DCt method. HPRT1 mRNA was used for
normalization. n = 2 per duplicate. **p < 0.05 vs. control MVs; ***p < 0.001 vs. control MVs; #p < 0.05 vs. IS-induced intermediate senescence MVs at the same time. (B)
Western blot analysis of SM22a from MVs-treated HASMCs was performed for different days. Equal protein loading was confirmed after probing with a-tubulin. The graph
presents data regarding densitometric bands analysis normalized to a-tubulin in terms of arbitrary units (AU). n = 2 per duplicate. ***p < 0.001 vs. 9 days at the same time.
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in atherogenesis and the development of VC [57,58]. As in the case
of the previous cytokines, the gene expression of both these mole-
cules was increased in HASMCs after incubation with MVs from IS-
treated HUVECs (intermediate senescence). Arterial inflammation
is common in patients with diabetes mellitus and CKD, and is asso-
ciated with increased levels of TNF-a. Moreover, TNF-a induces the
generation of osteogenic BMP-2 mRNA and leads to increased aor-tic calcium accumulation [59]. Finally, IL-6 gene expression was
evaluated, due to its direct implication in the inflammation process
and the calcium deposits in VSMCs [60]. Our results showed that
the IL-6 gene was overexpressed in HASMCs treated with MVs
from IS-treated endothelial cells. Furthermore, it has been reported
that because of ongoing inflammation, additional calcium-
phosphate crystals are formed, which might get aggregated [61].
Altogether, the measurement of pro-inflammatory gene expression
Fig. 7. Effect of MVs on pro-inflammatory genes in HASMCs. qPCR analysis of inflammatory mRNAs in HASMCs treated with control MVs and IS-treated HUVECs using the
DCt method; HPRT1 mRNA was used for normalization. n = 2 per duplicate. **p < 0.05 vs. control MVs; ***p < 0.001 vs. control MVs; #p < 0.05 vs. MVs obtained simultaneously
from IS-induced intermediate senescent cells.
964 M. Alique et al. / Computational and Structural Biotechnology Journal 18 (2020) 953–966in HASMCs after incubation with MVs from IS-treated endothelial
cells confirms that MVs released by IS-damaged endothelial cells
generate an inflammatory response in HASMCs, which could trig-
ger VC development. In this sense, the inhibition of the inflamma-
tory activity of VSMCs induced by endothelial MVs might be a
potential therapeutic target that can prevent vascular calcification
in CKD patients. Curiously, treatment with control MVs in HASMCscaused calcium deposits after 30 days, probably due to cellular
changes caused by the presence of MVs alone. These results con-
firm the fact that the inflammatory process is a condition associ-
ated with osteogenesis in the vasculature and that MVs from
damaged endothelial cells modulate the inflammatory process in
VSMCs. The presence of some cytokines in endothelial MVs might
provide prognostic information about the process of VC by MVs.
M. Alique et al. / Computational and Structural Biotechnology Journal 18 (2020) 953–966 9655. Conclusions
The uremic toxin IS generates stress in endothelial cells and
induces premature senescence and an increase in the release of
MVs that promote the development of VC. Our in vitro experimen-
tal design has shown for the first time that these MVs represent a
new VC mediator in the osteogenic transition mechanism in vascu-
lar smooth muscle cells. Finally, this study also demonstrates the
that MVs are involved in the inflammatory response of vascular
smooth muscle cells prior to VC development. These results might
be useful in the development of biomarkers and therapeutic tools
for preventing or treating patients with CVD and/or CKD at risk
of developing VC. Although these data need to be confirmed by
performing clinical studies, the results obtained actively support
the fact that plasma endothelial MVs could be used to identify
CKD patients at risk of developing VC and offer new perspectives
for achieving progress in future therapies designed to modulate
the altered activity of EVs. Further investigations on MVs are
required for using this information for the development of clinical
applications.
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